First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.

Heinz-Josef Lenz,Eric Van Cutsem,Maria Luisa Limón,Ka Yeung Mark Wong,Alain Hendlisz,Massimo Aglietta,Pilar García-Alfonso,Bart Neyns,Gabriele Luppi,Dana Backlund Cardin,Tomislav Dragovich,Usman Shah,Sandzhar Abdullaev,J. Gricar,Jean Marie Ledeine,Michael J. Overman,Sara Lonardi

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.

2021

Heinz-Josef Lenz
Eric Van Cutsem
Maria Luisa Limón
Ka Yeung Mark Wong
Alain Hendlisz
Massimo Aglietta
Pilar García-Alfonso
Bart Neyns
Gabriele Luppi
Dana Backlund Cardin
Tomislav Dragovich
Usman Shah
Sandzhar Abdullaev
J. Gricar
Jean Marie Ledeine
Michael J. Overman
Sara Lonardi

PURPOSENivolumab received US Food and Drug Administration approval as a single agent or in combination with ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient (MS...

Keywords:

Colorectal cancer
DNA mismatch repair
Oncology
first line
Medicine
food and drug administration
Internal medicine
Ipilimumab
low dose
Microsatellite instability
Nivolumab

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations